- Home
- AIRT vs FBIO Comparison
AIRT vs FBIO Comparison
Compare AIRT & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- FBIO
- Stock Information
- Founded
- AIRT 1980
- FBIO 2006
- Country
- AIRT United States
- FBIO United States
- Employees
- AIRT N/A
- FBIO N/A
- Industry
- AIRT Air Freight/Delivery Services
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- FBIO Health Care
- Exchange
- AIRT Nasdaq
- FBIO Nasdaq
- Market Cap
- AIRT 45.6M
- FBIO 48.2M
- IPO Year
- AIRT N/A
- FBIO N/A
- Fundamental
- Price
- AIRT $16.88
- FBIO $1.81
- Analyst Decision
- AIRT
- FBIO Strong Buy
- Analyst Count
- AIRT 0
- FBIO 4
- Target Price
- AIRT N/A
- FBIO $16.33
- AVG Volume (30 Days)
- AIRT 19.7K
- FBIO 957.9K
- Earning Date
- AIRT 11-11-2024
- FBIO 11-12-2024
- Dividend Yield
- AIRT N/A
- FBIO N/A
- EPS Growth
- AIRT N/A
- FBIO N/A
- EPS
- AIRT N/A
- FBIO N/A
- Revenue
- AIRT $281,814,000.00
- FBIO $82,624,000.00
- Revenue This Year
- AIRT N/A
- FBIO N/A
- Revenue Next Year
- AIRT N/A
- FBIO $81.63
- P/E Ratio
- AIRT N/A
- FBIO N/A
- Revenue Growth
- AIRT 5.20
- FBIO 31.68
- 52 Week Low
- AIRT $12.53
- FBIO $1.24
- 52 Week High
- AIRT $30.60
- FBIO $4.43
- Technical
- Relative Strength Index (RSI)
- AIRT 39.60
- FBIO 60.07
- Support Level
- AIRT $16.69
- FBIO $1.50
- Resistance Level
- AIRT $17.50
- FBIO $1.65
- Average True Range (ATR)
- AIRT 1.00
- FBIO 0.08
- MACD
- AIRT 0.19
- FBIO 0.04
- Stochastic Oscillator
- AIRT 30.94
- FBIO 91.11
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.